Tag Archives: NASDAQ:PBMD

Prima Biomed Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy assigned a Buy rating to Prima Biomed (NASDAQ: PBMD) today and set a price target of $7. The company’s shares opened today at $2.30. McCarthy said: “Prima announced data that will be presented at the

Maxim Group Reaffirms Their Buy Rating on Prima Biomed

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Prima Biomed (NASDAQ: PBMD) today and set a price target of $7. The company’s shares opened today at $1.77. McCarthy commented: “Prima updated the company’s financial position, reporting $10M in

Maxim Group Sticks to Their Buy Rating for Prima Biomed

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Prima Biomed (NASDAQ: PBMD) today and set a price target of $7. The company’s shares closed last Friday at $2.56. McCarthy noted: “Prima announced positive safety and early efficacy data

Analysts’ Top Healthcare Picks: PBMD, NK

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prima Biomed (NASDAQ: PBMD) and NantKwest (NASDAQ: NK) with bullish sentiments. Prima Biomed (NASDAQ: PBMD) In a report released today, Vernon Bernardino

Maxim Group Reiterates a Buy Rating on Prima Biomed

In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Prima Biomed (NASDAQ: PBMD), with a price target of $5. The company’s shares opened today at $0.82, close to its 52-week low of $0.72. McCarthy